Hereditary Testing Market Size, Share and Growth Outlook, 2026

Hereditary Testing Market Snapshot: Market Size, CAGR, and Growth Outlook (2021 to 2034)

The global Hereditary Testing Market size is forecast to increase from $21.04 Billion in 2026 to $62.59 Billion in 2034 at a CAGR of 14.6% between 2026 and 2034.

The Hereditary Testing market report provides detailed analysis and outlook of Hereditary Testing segments including By Test Type (Diagnostic Testing, Predictive & Presymptomatic Testing, Carrier Screening, Prenatal & Newborn Testing, Pharmacogenomic Testing), By Technology (Next-Generation Sequencing, PCR-based Testing, Microarray, Sanger Sequencing, Cytogenetic Testing), By Indication (Hereditary Cancer Testing, Hereditary Non-Cancer Testing ), By End User (Hospitals & Specialty Clinics, Diagnostic Laboratories, Academic & Research Institutes) across global and regional markets. Further, analysis and outlook across 21 countries in North America, Europe, Asia Pacific, Middle East, Africa, and South America are provided in the study.

Hereditary Testing Industry Overview

Genetic Testing Advances Strengthen Hereditary Disease Risk Assessment

The hereditary testing industry is experiencing rapid growth and technological advancement as healthcare providers increasingly utilize genetic information to support disease prevention, risk assessment, and personalized healthcare planning. Hereditary testing services are widely used across oncology, reproductive health, cardiovascular medicine, and rare disease diagnostics to identify inherited genetic variants associated with disease susceptibility. Advances in sequencing technologies, bioinformatics platforms, and clinical interpretation tools are enabling laboratories to deliver more comprehensive and clinically actionable genetic insights. As precision medicine initiatives continue to expand globally, hereditary testing is becoming an increasingly important component of preventive healthcare and individualized treatment planning.

Updated Standards Improve Carrier Screening Accuracy

Professional organizations are strengthening testing quality through enhanced clinical guidelines and technical standards. The American College of Medical Genetics and Genomics recently updated its technical recommendations for expanded carrier screening, reflecting the growing complexity of commercial genetic testing panels. The revised standards emphasize improved variant interpretation methodologies and address challenges associated with evaluating a rapidly expanding number of genes included in hereditary testing programs. By promoting greater consistency in genetic analysis and reporting practices, these updates support higher clinical sensitivity and specificity while helping healthcare providers deliver more reliable genetic counseling and risk assessment services.

Polygenic Risk Scores Enhance Personalized Genetic Evaluation

The hereditary testing industry is increasingly moving beyond traditional single-gene analysis toward more comprehensive genetic risk assessment models. Major diagnostic laboratories have begun integrating polygenic risk scores into commercial hereditary cancer testing panels. These advanced risk assessment tools combine information from monogenic mutations with numerous common genetic variants to generate a more detailed evaluation of disease susceptibility. By incorporating broader genetic information into risk calculations, polygenic risk scores provide clinicians with additional insights that can support personalized screening strategies, preventive interventions, and long-term healthcare planning. This development represents an important step toward more refined and individualized genetic risk prediction.

Regulatory Oversight Strengthens Consumer Protection in Genetic Testing

As direct-to-consumer hereditary testing services continue to expand, regulatory authorities are increasing oversight to ensure accurate communication of genetic risk information. Health agencies have introduced renewed requirements that obligate testing companies to clearly disclose the limitations of hereditary testing services, particularly for conditions influenced by significant environmental, lifestyle, or non-genetic factors. These directives are designed to reduce the risk of patient misunderstanding and promote informed decision-making regarding genetic test results. Enhanced regulatory scrutiny is encouraging greater transparency across the hereditary testing industry while supporting the responsible use of genetic information in both clinical and consumer healthcare settings.

Hereditary Testing Market Trends, Growth Drivers, Competitive Landscape, and Future Opportunities

The global Hereditary Testing market is witnessing increasing investments in innovation, product development, digital transformation, artificial intelligence integration, healthcare infrastructure expansion, and strategic partnerships across developed and emerging economies. Key Companies in the industry include- Illumina, Inc., Thermo Fisher Scientific Inc., F. Hoffmann-La Roche Ltd., Qiagen N.V., Myriad Genetics, Inc., Laboratory Corporation of America Holdings (LabCorp), Quest Diagnostics Incorporated, PerkinElmer, Inc., Bio-Rad Laboratories, Inc., Invitae Corporation. The Hereditary Testing market is expected to remain one of the most closely watched segments in the global healthcare industry, with companies focusing on niche market segments. As healthcare systems across the US, Europe, Asia-Pacific, Latin America, and Middle East & Africa continue to prioritize efficiency, access, and innovation, the Hereditary Testing industry outlook remains shaped by rising healthcare expenditure, demographic change, digital transformation, and product innovation.
The report provides detailed market analysis including-

• Growth Hereditary Testing Market size outlook across 3 scenarios- High growth, reference, and Low growth cases

• Market Trends, Drivers, Potential Opportunities, and Challenges faced by Hereditary Testing companies

• Porter’s Five forces analysis- Bargaining power of buyers and sellers, Threat of Substitutes and new entrants, and Intensity of competitive rivalry

• Detailed SWOT Analysis of global and regional Hereditary Testing markets

• Competitive analysis including business description, product analysis, and financial profiles

• Key country specific analysis detailing key factors shaping the short-term and long-term outlook

• Recent industry developments and news including mergers, acquisitions, product launches, expansions, and company announcements

Hereditary Testing Market Competitive Benchmarking and Company Analysis

Leading companies in Hereditary Testing industry include- Illumina, Inc., Thermo Fisher Scientific Inc., F. Hoffmann-La Roche Ltd., Qiagen N.V., Myriad Genetics, Inc., Laboratory Corporation of America Holdings (LabCorp), Quest Diagnostics Incorporated, PerkinElmer, Inc., Bio-Rad Laboratories, Inc., Invitae Corporation. The Hereditary Testing market remains moderately to highly fragmented, with competition expected to intensify as companies accelerate investments in innovation, geographic expansion, strategic partnerships, and portfolio diversification through 2034. In developed markets such as the United States, Germany, France, the United Kingdom, and Canada, competition is increasingly centered on innovation, reimbursement positioning, and value-based healthcare solutions. Meanwhile, emerging markets including China, India, Brazil, and countries across the Middle East and Africa continue to present significant opportunities for expansion due to rising healthcare expenditure, growing patient populations, and increasing access to healthcare services.

What to expect in US Hereditary Testing Markets in 2026 and beyond- Market Size, Share, Growth Rate, and Forecast to 2034

The US healthcare expenditure is forecast to reach $8.2 Trillion in 2034 from $5.5 Trillion in 2026 based on the National Health Expenditure Accounts (NHEA) data. With an aging population, rising chronic disease burden, and increasing migration toward minimally invasive and outpatient care, the Hereditary Testing market remains one of the strongest-performing segments in the country.
The US Hereditary Testing Companies are opting new business models, optimized pricing models, industry partnerships, and AI-enabled back end transformations to enhance efficiency and cost management. The US Hereditary Testing market faces successive waves of challenging trends, with strong opportunities across select segments. The CMS plan to implement Medicaid from 2027 is driving states to build eligibility verification systems throughout 2026. Looking ahead to 2034, we anticipate stronger results underpinned by opportunities exist across Hereditary Testing industry. On the medical device front, over 7,000 device manufacturers continue to gain from increasing demand from demand for implantable devices, surgical instruments, monitoring equipment, and diagnostic systems.

Canada- Proximity to the US and healthcare similarities to EU5 countries fuel sales of Canadian Hereditary Testing markets

Canada's strong Hereditary Testing sales performance is underpinned by an aging population and a well-developed healthcare infrastructure. Steady growth in new brand spending in rural and urban locations fuel the long-term prospects of small and medium-sized enterprises across medical, diagnostic, and therapeutic devices. The Canadian Hereditary Testing market presents significant opportunities for U.S. exporters of medical devices, with the U.S. being Canada’s largest trading partner for this sector. Potential advantages including specialized materials, advanced manufacturing techniques, and digital technologies support the launch of new products in the country.

Germany Hereditary Testing Trends and Perspectives to 2034- Financial sustainability, hospital restructuring, demographic pressures, and digitization of care delivery continue to shape the German healthcare industry.

Germany continues to remain the largest Hereditary Testing market in Europe, driven by over €600 Billion healthcare expenditure, €12 Billion medical device R&D expenditure, statutory health insurance system covering 90% German population, nationwide rollout of the electronic patient record (ePA), and large-volume of Hereditary Testing population. In particular, Research and development in Germany fuels the commercialization of cutting-edge technologies. Companies across the Germany Hereditary Testing industry value chain are focusing on both domestic markets and exports. The country is also driving digital adoption with the Hospital Future Act driving hospitals to upgrade their information systems by 2027. Over the forecast period, aging population, rising healthcare costs, and increasing procedural volumes drive the Hereditary Testing market outlook.

France Market Size, Growth Rate, and Forecast Analysis to 2034- Universal healthcare system, high public healthcare expenditure, and strong government support Hereditary Testing sales through 2034

France Hereditary Testing companies are emphasizing on opportunities for rapid, at-scale innovation to boost profitability over the long-term. The country’s National Health Insurance spending target (ONDAM) estimates 3.7% growth in the country’s healthcare expenditure. Over the forecast period, expenditure control measures, chronic disease management initiatives, workforce reforms, and efforts to improve system efficiency drive the long-term prospects.
The biggest 2026 policy frame is the PLFSS 2026. The law sets the Maladie branch spending target at €271.4 billion for 2026 and fixes the ONDAM at €117.5 billion for city care, €112.8 billion for health establishments, and €18.3 billion for elderly-care establishments and services. France’s market is also being pulled by demographics. INSEE estimates that on 1 January 2026 France had 69.1 million inhabitants, with 22% aged 65 or over. INSEE also reported that 2025 births were 645,000 and deaths were 651,000, producing a negative natural balance of about 6,000 for the first time since the end of the Second World War.

UK Hereditary Testing Market Size, Share, and Growth Projections to 2034- Rapid growth driven by new and existing brands across the industry value chain

Small high-need consumer segments remain key priority of Hereditary Testing distributors in the UK industry. Continuous launch of new products coupled with high expenditures support the market outlook. The UK Government financing remains the dominant funding source at 81.3% of total healthcare expenditure, or £280 billion in 2025. According to the ONS, total healthcare spending grew 7.7% nominally and 3.9% in real terms from 2024 to 2025. Similarly, out-of-pocket spending was £49 billion (14.1%) and voluntary health insurance was £9.5 billion (2.8%). The market is driven by rapid digital adoption with NHS England’s plan to give more than 500,000 staff access to new AI tools.

China Hereditary Testing Market Growth Drivers, Revenue Trends, and Forecast- Medical insurance coverage is rapidly expanding over the past few years

China Hereditary Testing market is undergoing a structural shift from hospital-centric care toward a more integrated system emphasizing primary care, outpatient services, and long-term care. Chinese local players are emerging as a strong pillar of Hereditary Testing industry, offering opportunities for both competition and partnership. Over the forecast period, new and innovative product launches remain key elements driving market outlook. China's healthcare industry is increasingly centered on expanding healthcare capacity, improving access to advanced treatments, and reducing dependence on imported technologies.
The National Healthcare Security Administration reported that by end-2024, China’s basic medical insurance covered 1.32662 billion people and the coverage rate was 95%. Regional disparities in consumer spending trends continue to become more pronounced in the Chinese Hereditary Testing industry. Over the forecast period, demand will keep shifting toward geriatrics, chronic disease management, rehabilitation, long-term care, and outpatient care, while pricing pressure will remain intense in drugs and consumables because reimbursement.

India Hereditary Testing Market Landscape: Current Size and Long-Term Growth Outlook - Increased pricing pressures in US market is encouraging domestic vendors to expand across India

Indian Hereditary Testing market is witnessing the rapid emergence of an ecosystem that brings together diverse companies across the industry value chain. Further, large-scale healthcare public and private investments and a steady growth in chronic conditions is driving sales of pharmaceuticals and medical devices. Further, non-retail channel is experiencing volume decrease and patients are migrating to the retail. Indian medical device firms are also combining precision engineering with lower labor costs to make world-class diagnostics, robotics, and critical care devices.

Brazil Hereditary Testing market remains price-driven, with products domestically manufactured and accessibility offering potential opportunities

Healthcare expenditure in Brazil exceeds 10% of GDP, with the country among the highest healthcare spenders in Latin America. ANS reported 53.2 million medical-plan beneficiaries in December 2025, while IBGE projects a steady rise in older-age cohorts, with people aged 60+ already representing about 23% of the population. The price sensitive market access is broad through the public system, private coverage adds a sizeable premium layer, and reimbursement, procurement, and hospital efficiency remain key buying drivers.

Middle East and Africa Hereditary Testing Industry Trends and Perspectives to 2034

According to the World Bank, the Middle East and North Africa population exceeds 500 million, while Sub-Saharan Africa's population exceeds 1.2 billion, making the broader MEA region one of the fastest-growing healthcare demand centers globally. The GCC countries including Saudi Arabia, United Arab Emirates, Qatar, and Kuwait continue to account for a disproportionately large share of regional healthcare spending. Government-led programs such as Saudi Arabia's Vision 2030 are accelerating investments in hospital infrastructure, private-sector participation, medical technology adoption, and healthcare digitalization. On the other hand, South Africa, Egypt, Nigeria, and Kenya remain key healthcare markets due to their large populations, expanding private healthcare sectors, and growing investments in healthcare delivery systems.

Hereditary Testing Market Segmentation

By Test Type
Diagnostic Testing
Predictive & Presymptomatic Testing
Carrier Screening
Prenatal & Newborn Testing
Pharmacogenomic Testing
By Technology
Next-Generation Sequencing
PCR-based Testing
Microarray
Sanger Sequencing
Cytogenetic Testing
By Indication
Hereditary Cancer Testing
Hereditary Non-Cancer Testing
By End User
Hospitals & Specialty Clinics
Diagnostic Laboratories
Academic & Research Institutes

Top Companies in Hereditary Testing Industry

Illumina, Inc.
Thermo Fisher Scientific Inc.
F. Hoffmann-La Roche Ltd.
Qiagen N.V.
Myriad Genetics, Inc.
Laboratory Corporation of America Holdings (LabCorp)
Quest Diagnostics Incorporated
PerkinElmer, Inc.
Bio-Rad Laboratories, Inc.
Invitae Corporation

Countries Included

• North America- US, Canada, Mexico

• Europe- Germany, France, UK, Spain, Italy, Nordics, Others

• Asia Pacific- China, India, Japan, South Korea, Australia, Southeast Asia, Others

• Latin America- Brazil, Argentina, Others

• Middle East and Africa- Saudi Arabia, UAE, Other Middle East, South Africa, Other Africa

Latest Market Updates In Healthcare

Support this report with fresh, same-industry updates that strengthen topical depth and internal linking.

Market Update

Rise of Functional and Clinical-Grade Skincare

The rising geopolitical and tariff-related uncertainties, in particular, amidst United States’ renewed protectionist trade stance continues to driv...

June 2025